Skip to main content
SpringerLink
Log in
Book cover

Advances in Asthma pp 71–81Cite as

Periostin as a Biomarker for Type 2 Asthma

  • Chapter
  • First Online:

  • 2613 Accesses

Abstract

Periostin is a protein having two characteristics—an extracellular matrix (ECM) protein important for maintaining tissue or organ structures and in generating fibrosis by binding to other ECM proteins and a matricellular protein transducing intracellular signaling by binding to several integrins on the cell surface. IL-4 and IL-13, signature type 2 cytokines abundantly expressed in the inflamed sites of asthma, induce periostin in several tissue-resident cells—fibroblasts, airway epithelial cells, and endothelial cells—and then periostin contributes to generating thick basement membranes, a typical histological feature in asthma patients. Periostin would play a role in accelerating airway allergic inflammation in asthma by acting as a matricellular protein. Serum periostin has characteristics as a biomarker, reflecting both type 2 inflammation and remodeling/fibrosis in asthma patients. These characteristics are useful for stratifying asthma patients and can predict the ICS resistance or efficacy of molecularly targeted drugs such as IL-4/IL-13 antagonists for asthma patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Takeshita S, Kikuno R, Tezuka K, Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993;294:271–8.

    Article  CAS  Google Scholar 

  2. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor β. J Bone Miner Res. 1999;14:1239–49.

    Article  CAS  Google Scholar 

  3. Izuhara K, Arima K, Ohta S, Suzuki S, Inamitsu M, Yamamoto K. Periostin in allergic inflammation. Allergol Int. 2014;63:143–51.

    Article  CAS  Google Scholar 

  4. Izuhara K, Nunomura S, Nanri Y, Ogawa M, Ono J, Mitamura Y, et al. Periostin in inflammation and allergy. Cell Mol Life Sci. 2017;74:4293–303.

    Article  CAS  Google Scholar 

  5. O’Dwyer DN, Moore BB. The role of periostin in lung fibrosis and airway remodeling. Cell Mol Life Sci. 2017;74:4305–14.

    Article  Google Scholar 

  6. Murota H, Lingli Y, Katayama I. Periostin in the pathogenesis of skin diseases. Cell Mol Life Sci. 2017;74:4321–8.

    Article  CAS  Google Scholar 

  7. Prakoura N, Chatziantoniou C. Periostin in kidney diseases. Cell Mol Life Sci. 2017;74:4315–20.

    Article  CAS  Google Scholar 

  8. Yoshida S, Nakama T, Ishikawa K, Nakao S, Sonoda KH, Ishibashi T. Periostin in vitreoretinal diseases. Cell Mol Life Sci. 2017;74:4329–37.

    Article  CAS  Google Scholar 

  9. Cui D, Huang Z, Liu Y, Ouyang G. The multifaceted role of periostin in priming the tumor microenvironments for tumor progression. Cell Mol Life Sci. 2017;74:4287–91.

    Article  CAS  Google Scholar 

  10. Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci. 2014;71:1279–88.

    Article  CAS  Google Scholar 

  11. Nishida M, Sato Y, Uemura A, Narita Y, Tozaki-Saitoh H, Nakaya M, et al. P2Y6 receptor-Gα12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J. 2008;27:3104–15.

    Article  CAS  Google Scholar 

  12. Liu AY, Zheng H, Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol. 2014;37:150–6.

    Article  Google Scholar 

  13. Yuyama N, Davies DE, Akaiwa M, Matsui K, Hamasaki Y, Suminami Y, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine. 2002;19:287–96.

    Article  CAS  Google Scholar 

  14. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118:98–104.

    Article  CAS  Google Scholar 

  15. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, et al. Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A. 2010;107:14170–5.

    Article  CAS  Google Scholar 

  16. Shoda T, Futamura K, Kobayashi F, Saito H, Matsumoto K, Matsuda A. Cell type-dependent effects of corticosteroid on periostin production by primary human tissue cells. Allergy. 2013;68:1467–70.

    Article  CAS  Google Scholar 

  17. Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K, et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J. 2011;37:1119–27.

    Article  CAS  Google Scholar 

  18. Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol. 2013;132:305–12.

    Article  CAS  Google Scholar 

  19. Matsusaka M, Kabata H, Fukunaga K, Suzuki Y, Masaki K, Mochimaru T, et al. Phenotype of asthma related with high serum periostin levels. Allergol Int. 2015;64:175–80.

    Article  CAS  Google Scholar 

  20. Kim MA, Izuhara K, Ohta S, Ono J, Yoon MK, Ban GY, et al. Association of serum periostin with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2014;113:314–20.

    Article  CAS  Google Scholar 

  21. Bobolea I, Barranco P, Del Pozo V, Romero D, Sanz V, Lopez-Carrasco V, et al. Sputum periostin in patients with different severe asthma phenotypes. Allergy. 2015;70:540–6.

    Article  CAS  Google Scholar 

  22. Simpson JL, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Periostin levels and eosinophilic inflammation in poorly-controlled asthma. BMC Pulm Med. 2016;16:67.

    Article  Google Scholar 

  23. Sehra S, Yao W, Nguyen ET, Ahyi AN, Tuana FM, Ahlfeld SK, et al. Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation. J Immunol. 2011;186:4959–66.

    Article  CAS  Google Scholar 

  24. Gordon ED, Sidhu SS, Wang ZE, Woodruff PG, Yuan S, Solon MC, et al. A protective role for periostin and TGF-β in IgE-mediated allergy and airway hyperresponsiveness. Clin Exp Allergy. 2012;42:144–55.

    Article  CAS  Google Scholar 

  25. Bentley JK, Chen Q, Hong JY, Popova AP, Lei J, Moore BB, et al. Periostin is required for maximal airways inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol. 2014;134:1433–42.

    Article  CAS  Google Scholar 

  26. Kanemitsu Y, Ito I, Niimi A, Izuhara K, Ohta S, Ono J, et al. Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma. Am J Respir Crit Care Med. 2014;190:472–4.

    Article  Google Scholar 

  27. Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122:2590–600.

    Article  CAS  Google Scholar 

  28. Taniguchi K, Arima K, Masuoka M, Ohta S, Shiraishi H, Ontsuka K, et al. Periostin controls keratinocyte proliferation and differentiation by interacting with the paracrine IL-1α/IL-6 loop. J Invest Dermatol. 2014;134:1295–304.

    Article  CAS  Google Scholar 

  29. Uchida M, Shiraishi H, Ohta S, Arima K, Taniguchi K, Suzuki S, et al. Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;46:677–86.

    Article  CAS  Google Scholar 

  30. Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol. 2008;1:289–96.

    Article  CAS  Google Scholar 

  31. Noguchi T, Nakagome K, Kobayashi T, Uchida Y, Soma T, Nakamoto H, et al. Periostin upregulates the effector functions of eosinophils. J Allergy Clin Immunol. 2016;138:1449–52.

    Article  CAS  Google Scholar 

  32. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–25.

    Article  CAS  Google Scholar 

  33. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–95.

    Article  CAS  Google Scholar 

  34. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647–54.

    Article  CAS  Google Scholar 

  35. Matsusaka M, Fukunaga K, Kabata H, Izuhara K, Asano K, Betsuyaku T. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract. 2018;6:274–6.

    Article  Google Scholar 

  36. James A, Janson C, Malinovschi A, Holweg C, Alving K, Ono J, et al. Serum periostin relates to type-2 inflammation and lung function in asthma: data from the large population-based cohort Swedish GA(2)LEN. Allergy. 2017;72:1753–60.

    Article  CAS  Google Scholar 

  37. Hinks TS, Brown T, Lau LC, Rupani H, Barber C, Elliott S, et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol. 2016;138:61–75.

    Article  CAS  Google Scholar 

  38. Nagasaki T, Matsumoto H, Kanemitsu Y, Izuhara K, Tohda Y, Horiguchi T, et al. Using exhaled nitric oxide and serum periostin as a composite marker to identify severe/steroid-insensitive asthma. Am J Respir Crit Care Med. 2014;190:1449–52.

    Article  Google Scholar 

  39. Nagasaki T, Matsumoto H, Kanemitsu Y, Izuhara K, Tohda Y, Kita H, et al. Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes. J Allergy Clin Immunol. 2014;133:1474–7.

    Article  Google Scholar 

  40. Kato G, Takahashi K, Izuhara K, Komiya K, Kimura S, Hayashi S. Markers that can reflect asthmatic activity before and after reduction of inhaled corticosteroids: a pilot study. Biomark Insights. 2013;8:97–105.

    Article  Google Scholar 

  41. Matsumoto H. Serum periostin: a novel biomarker for asthma management. Allergol Int. 2014;63:153–60.

    Article  CAS  Google Scholar 

  42. Izuhara K, Matsumoto H, Ohta S, Ono J, Arima K, Ogawa M. Recent developments regarding periostin in bronchial asthma. Allergol Int. 2015;64(Suppl):S3–S10.

    Article  Google Scholar 

  43. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–98.

    Article  CAS  Google Scholar 

  44. Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4:781–96.

    Article  CAS  Google Scholar 

  45. Brightling CE, Chanez P, Leigh R, O’Byrne PM, Korn S, She D, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:692–701.

    Article  CAS  Google Scholar 

  46. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;376:1090–1.

    Google Scholar 

  47. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44.

    Article  CAS  Google Scholar 

  48. Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–11.

    Article  CAS  Google Scholar 

  49. Tajiri T, Matsumoto H, Gon Y, Ito R, Hashimoto S, Izuhara K, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy. 2016;71:1472–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Dr. Dovie R. Wylie for the critical review of this manuscript. We also thank the following colleagues and collaborators for contributing to the present work: Go Takayama, Masaru Uchida, Miho Masuoka, Hiroshi Shiraishi, Kanako Ontsuka, Kazuto Taniguchi, Yasutaka Mitamura, Tomohito Yoshihara, Kazuhiko Arima, Shoichi Suzuki, Shoichiro Ohta, Go Kato, Koichiro Takahashi, Shin-ichiro Hayashi (Saga Medical School), Noriko Yuyama (Genox Research, Inc.), Akihiro Ishida, Nobuo Ohta (Yamagata University), Hiroshi Fujishima (Tsurumi University), Naoko Okada, Kenji Matsumoto (National Research Institute for Child Health and Development Laboratory), Yoshihiro Kanemitsu, Tadao Nagasaki, Tomoko Tajiri, Hisako Matsumoto (Kyoto University), Masako Matsuzaka, Koichi Fukunaga (Keio University), Koichiro Asano (Tokai University), Yorihisa Kotobuki, Ichiro Katayama (Osaka University), Kenzen Kou, Yukie Yamaguchi, Michiko Aihara (Yokohama City University), Timothy Hinks, Peter Howarth (Southampton University Hospital), Mi-Ae Kim, Hae-Sim Park (Ajou University), Anna James, Sven-Erik Dahlen (Karolinska Institutet), Ayami Kamei, Yoshinori Azuma (Shino-Test Co.), Simon J. Conway (Indiana University), Masaki Okamoto, Tomoaki Hoshino, and Kiminori Fujimoto (Kurume University).

Author information

Authors and Affiliations

  1. Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga-shi, Saga, Japan

    Kenji Izuhara, Satoshi Nunomura, Junya Ono, Masayuki Takai & Yasuhiro Nanri

  2. Shino-Test Corporation, Sagamihara-shi, Kanagawa, Japan

    Junya Ono & Masayuki Takai

Authors
  1. Kenji Izuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoshi Nunomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junya Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masayuki Takai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasuhiro Nanri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenji Izuhara .

Editor information

Editors and Affiliations

  1. Department of Hematology and Respiratory Medicine, Kochi Medical School, Nankoku-shi, Kochi, Japan

    Akihito Yokoyama

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Izuhara, K., Nunomura, S., Ono, J., Takai, M., Nanri, Y. (2019). Periostin as a Biomarker for Type 2 Asthma. In: Yokoyama, A. (eds) Advances in Asthma. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-13-2790-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-2790-2_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-2789-6

  • Online ISBN: 978-981-13-2790-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation